These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1073 related items for PubMed ID: 19641300

  • 1. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK, Gruber FX, Wee L, Hovland R, Hjorth-Hansen H, Gedde Dahl T, Meyer P.
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
    Agirre X, Román-Gómez J, Vázquez I, Jiménez-Velasco A, Larráyoz MJ, Lahortiga I, Andreu EJ, Márquez J, Beltrán de Heredia JM, Odero MD, Prósper F, Calasanz MJ.
    Cancer Genet Cytogenet; 2005 Jul 01; 160(1):22-6. PubMed ID: 15949566
    [Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
    Qin YZ, Jiang B, Jiang Q, Zhang Y, Jiang H, Li JL, Zhu HH, Li LD, Liu YR, Chen SS, Huang XJ.
    Acta Haematol; 2008 Jul 01; 120(3):146-9. PubMed ID: 19039205
    [Abstract] [Full Text] [Related]

  • 7. BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
    Gadzicki D, von Neuhoff N, Steinemann D, Just M, Büsche G, Kreipe H, Wilkens L, Schlegelberger B.
    Cancer Genet Cytogenet; 2005 Jun 01; 159(2):164-7. PubMed ID: 15899391
    [Abstract] [Full Text] [Related]

  • 8. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y, Hardling M, Olsson B, Hezaveh R, Ricksten A, Stockelberg D, Wadenvik H.
    Ann Hematol; 2006 Dec 01; 85(12):841-7. PubMed ID: 17006667
    [Abstract] [Full Text] [Related]

  • 9. Complex chromosome rearrangements may locate the bcr/abl fusion gene sites other than 22q11.
    Sessarego M, Fugazza G, Bruzzone R, Ballestrero A, Miglino M, Bacigalupo A.
    Haematologica; 2000 Jan 01; 85(1):35-9. PubMed ID: 10629589
    [Abstract] [Full Text] [Related]

  • 10. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
    Andrikovics H, Nahajevszky S, Szilvási A, Bors A, Adám E, Kozma A, Kajtár B, Barta A, Poros A, Tordai A.
    Hematol Oncol; 2007 Sep 01; 25(3):143-7. PubMed ID: 17530620
    [Abstract] [Full Text] [Related]

  • 11. BCR/ABL rearrangement in two cases of Philadelphia chromosome negative chronic myeloid leukemia: deletion on the derivative chromosome 9 may or not be present.
    Batista DA, Hawkins A, Murphy KM, Griffin CA.
    Cancer Genet Cytogenet; 2005 Dec 01; 163(2):164-7. PubMed ID: 16337861
    [Abstract] [Full Text] [Related]

  • 12. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G, Kurosu T, Arai A, Murakami N, Miura O.
    Cancer Genet Cytogenet; 2010 May 01; 199(1):56-61. PubMed ID: 20417871
    [Abstract] [Full Text] [Related]

  • 13. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
    Joshi D, Chandrakala S, Korgaonkar S, Ghosh K, Vundinti BR.
    Gene; 2014 Jun 01; 542(2):109-12. PubMed ID: 24680705
    [Abstract] [Full Text] [Related]

  • 14. A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL.
    Onozawa M, Fukuhara T, Takahata M, Yamamoto Y, Miyake T, Maekawa I.
    Ann Hematol; 2003 Sep 01; 82(9):593-5. PubMed ID: 12898186
    [Abstract] [Full Text] [Related]

  • 15. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
    Bennour A, Beaufils N, Sennana H, Meddeb B, Saad A, Gabert J.
    J Clin Pathol; 2010 Aug 01; 63(8):737-40. PubMed ID: 20702476
    [Abstract] [Full Text] [Related]

  • 16. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
    Wang L, Knight K, Lucas C, Clark RE.
    Haematologica; 2006 Feb 01; 91(2):235-9. PubMed ID: 16461309
    [Abstract] [Full Text] [Related]

  • 17. Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
    Phan CL, Megat Baharuddin PJ, Chin LP, Zakaria Z, Yegappan S, Sathar J, Tan SM, Purushothaman V, Chang KM.
    Cancer Genet Cytogenet; 2008 Jan 01; 180(1):60-4. PubMed ID: 18068536
    [Abstract] [Full Text] [Related]

  • 18. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression.
    Lee DS, Lee YS, Yun YS, Kim YR, Jeong SS, Lee YK, She CJ, Yoon SS, Shin HR, Kim Y, Cho HI.
    Genes Chromosomes Cancer; 2003 Jul 01; 37(3):291-9. PubMed ID: 12759927
    [Abstract] [Full Text] [Related]

  • 19. A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
    Li X, Yang J, Chen X, Liu J, Li H, Zheng J, He Y, Chen Z, Huang S.
    Cancer Genet Cytogenet; 2007 Jul 15; 176(2):166-8. PubMed ID: 17656262
    [Abstract] [Full Text] [Related]

  • 20. Generation of the BCR/ABL fusion gene in a Philadelphia chromosome-negative chronic myeloid leukaemia: insertion of 5.6 Mb of 9q34 into the BCR region of chromosome 22.
    Valle L, Fernández V, Pérez-Pons C, Sánchez FG, Benítez J, Urioste M.
    Hematol Oncol; 2006 Jun 15; 24(2):86-8. PubMed ID: 16598834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.